Tags » Cetuximab

EDITOR’S CHOICE – The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab

Journal: Recent Patents on Biotechnology

Author(s): Tasha R. Serna-Gallegos, Christopher J. La-Fargue, Krishnansu S. Tewari

Graphical Abstract:


Objective: Fully humanized monoclonal antibodies have revolutionized the treatment of many solid tumors, including ovarian, lung, colorectal, and breast cancer. 145 more words

Bentham Science Publishers

Cetuximab Market: Key Drivers, Restrain and Future Prospect Forecast by 2021

Global Cetuximab Market is segmented, by Geographical Region into United States, China, Europe, and Japan. Cetuximab comes across as an epidermal growth factor receptor (EGFR) inhibitor used to treat metastatic non-small cell lung cancer, head and neck cancer, and metastatic colorectal cancer. 413 more words


Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.


EGFR antibodies have shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with squamous cell histology. We hypothesised that EGFR copy number by fluorescence in-situ hybridisation (FISH) can identify patients most likely to benefit from these drugs combined with chemotherapy and we aimed to explore the activity of cetuximab with chemotherapy in patients with advanced NSCLC who are EGFR FISH-positive. 476 more words


Increasing Prevalence of Colorectal Cancer Along with Growing Geriatric Population are Likely to Impel the Growth of Colorectal Cancer Therapeutics Market in Future

Colorectal Cancer Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2024

The global colorectal cancer therapeutics market is segmented into treatment type such as chemotherapy, targeted therapy, immunotherapy, surgery, radiation therapy and embolization. 683 more words

Research Nester